PMC:7784786 / 441-713 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":77,"end":82},"obj":"Gene"},{"id":"26","span":{"begin":84,"end":88},"obj":"Gene"},{"id":"27","span":{"begin":93,"end":98},"obj":"Gene"},{"id":"30","span":{"begin":172,"end":180},"obj":"Species"},{"id":"34","span":{"begin":194,"end":204},"obj":"Chemical"},{"id":"35","span":{"begin":245,"end":255},"obj":"Chemical"},{"id":"38","span":{"begin":148,"end":162},"obj":"Disease"},{"id":"39","span":{"begin":163,"end":171},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Gene:3458"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Gene:3569"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Gene:7124"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Tax:9606"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:C000597346"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:C000597346"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:D016638"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"sociated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to redu"}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":100,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"sociated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to redu"}